CSL is setting its sights on the US$21.6 billion (AU$33.54 billion) asthma market with the development of a groundbreaking drug designed to combat a lung inflammation that primarily triggers the chronic respiratory condition.
The introduction of this therapy, named trabikibart or CSL311, is poised to position CSL as a household name, especially since over 10 percent of Australia’s population, equivalent to 2.7 million individuals, grapple with asthma.
